<DOC>
	<DOCNO>NCT00082706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , gemcitabine , cisplatin , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase II trial study well give fluorouracil together leucovorin , gemcitabine , cisplatin work treat patient metastatic unresectable adenocarcinoma urothelium urachal remnant ( part bladder ) .</brief_summary>
	<brief_title>Fluorouracil , Leucovorin , Gemcitabine , Cisplatin Treating Patients With Metastatic Unresectable Adenocarcinoma Urothelium Urachal Remnant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate overall survival patient metastatic unresectable adenocarcinoma urothelium urachal remnant treat fluorouracil , leucovorin calcium , gemcitabine , cisplatin . Secondary - Determine toxicity regimen patient . OUTLINE : Patients stratify accord diagnosis ( adenocarcinoma urothelium v adenocarcinoma urachal remnant ) . Patients receive fluorouracil vein ( IV ) continuously , leucovorin calcium IV daily , cisplatin IV daily day 1-5 gemcitabine IV day 1 5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3-6 month . PROJECTED ACCRUAL : A total 23-46 patient ( 7-18 adenocarcinoma urachal remnant 16-28 adenocarcinoma urothelium ) accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologic proof cancer originate urinary tract adenocarcinoma predominant ( &gt; /= 50 % ) histology . Dr. Czerniak and/or Dr. Tamboli consult equivocal case mixed histology . The Study Chairman final arbiter question mixed histology . 2 . Bidimensionally measurable disease . All patient must measurable evaluable disease . In general , liver lung lesion least 1 cm , patient nodeonly disease lesion &gt; /= 1.5 cm great dimension . Patients disease confine bone may eligible measurable lytic defect , softtissue component present . Those without measurable disease may eligible serum marker elevate ( &gt; /= 4 x ULN ) ( ie : CEA , CA125 , CA199 , bhCG , etc ) . 3 . ( # 2 cont 'd ) The Study Chairman final arbiter question related measurability . Patients threedimensional mass pelvic sidewall fixation bladder examination anesthesia consider measurable disease . 4 . Patients eligible evidence metastatic disease , tumor surgically unresectable . In absence grossly metastatic disease , patient see evaluated member Urology staff assess potential resection . 5 . Patients must adequate physiologic reserve evidence : • Life expectancy least 9 month ( base comorbidity ) &amp; least 9 week base natural history cancer . • Zubrod Performance Status ( PS ) &lt; /= 2 ; 3 recent onset due entirely cancer comorbidity , especially compromise performance status due uncontrolled pain expect rapidly reversible therapy start . 6 . ( # 5 cont 'd ) • Adequate bone marrow function define absolute neutrophil count &gt; /= 1,800 platelet count &gt; /= 150,000 . Supranormal value judge benign inconsequential etiology acceptable . • Transaminase ( either SGPT SGOT ) &lt; /= 2x upper limit normal . • Conjugated bilirubin &lt; /= 2x upper limit normal . • Creatinine clearance ( either measure estimate use formula Cockcroft Gault ) &gt; /= 35 mL/min : CLcr = [ ( 140age ) • wt ( kg ) ] / [ 72 •Creat ( mg/dL ) ] ( For female , x 0.85 ) 7 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 8 . Patients must least 6 week pelvic irradiation , must 10 % bone marrow irradiate . 9 . Patients history cardiac disease , evidence ischemic heart disease EKG must adequate cardiac function EF &gt; /= 40 % participate . 10 . Patient must least 18 year age participate study . 1 . Patients metastases bladder primary adenocarcinoma arise outside urinary tract ineligible . 2 . Overt psychosis mental disability otherwise incompetent give inform consent . 3 . A life threaten illness ( unrelated tumor ) would prevent completion protocol therapy . 4 . Pregnant nursing woman , drug therapy regimen , support medication pose significant potential risk fetus newborn . 5 . Patients second malignancy eligible provide expect outcome second cancer interfere delivery therapy , assessment response . 6 . Patients uncontrolled CNS metastasis eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
</DOC>